{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:07:20Z","timestamp":1794362840372,"version":"4.9.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ygyno.2021.07.008","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T02:30:48Z","timestamp":1625884248000},"page":"433-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["The effectiveness of monotherapy with PI3K\/AKT\/mTOR pathway inhibitors in ovarian cancer: A meta-analysis"],"prefix":"10.1016","volume":"163","author":[{"given":"Phyllis","family":"van der Ploeg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniek","family":"Uittenboogaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.J.","family":"Thijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans M.","family":"Westgeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid A.","family":"Boere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrina","family":"Lambrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"van de Stolpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud L.M.","family":"Bekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen M.J.","family":"Piek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.07.008_bb0005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/diagnostics7020024","article-title":"A resident\u2019s perspective of ovarian cancer","volume":"7","author":"Smith","year":"2017","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0010","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0015","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5732\/cjc.014.10289","article-title":"The PI3K\/Akt\/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges","volume":"34","author":"Cheaib","year":"2015","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","article-title":"Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance","volume":"59","author":"Ediriweera","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ctrv.2017.07.005","article-title":"Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: from laboratory to patients","volume":"59","author":"Janku","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0035","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0040","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00404-014-3377-3","article-title":"PI3K\/AKT\/mTOR signaling pathway as a therapeutic target for ovarian cancer","volume":"290","author":"Li","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0045","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2015.02.003","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in ovarian cancer","volume":"137","author":"Mabuchi","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0055","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/cancers12010093","article-title":"PIK3CA gene mutations in solid malignancies: association with clinicopathological parameters and prognosis","volume":"12","author":"Alqahtani","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0060","doi-asserted-by":"crossref","first-page":"102021","DOI":"10.1016\/j.ctrv.2020.102021","article-title":"Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer","volume":"86","author":"Huang","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0065","article-title":"Efficacy of PI3K\/AKT\/mTOR pathway inhibitors for the treatment of advanced solid cancers: a literature-based meta-analysis of 46 randomised control trials","volume":"13","author":"Li","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0075","series-title":"PROSPERO","article-title":"The effectiveness of monotherapy with PI3K\/AKT\/mTOR inhibitors in ovarian cancer: a systematic review (CRD42020164469)","author":"Uittenboogaard","year":"2020"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0085","series-title":"Common Terminology Criteria for Adverse Events (CTCAE)","author":"National Cancer Institute","year":"2021"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0090","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0095","series-title":"How to Conduct a Meta-analysis of Proportions in R: A Comprehensive Tutorial","author":"Wang","year":"2018"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0100","first-page":"2050","article-title":"A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA","volume":"24","author":"Banerji","year":"2018","journal-title":"Mutat. Breast Gynecol. Cancers"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0105","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1158\/1078-0432.CCR-14-1315","article-title":"First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer","volume":"20","author":"Blagden","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0110","series-title":"A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors","first-page":"4173","volume":"18","author":"Hong","year":"2012"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0115","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1158\/1078-0432.CCR-15-1665","article-title":"First-in-human phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies","volume":"22","author":"Munster","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.06.022","article-title":"Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study","volume":"123","author":"Behbakht","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0125","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2015.12.025","article-title":"Temsirolimus in women with platinum-refractory\/resistant ovarian cancer or advanced\/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)","volume":"140","author":"Emons","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0130","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.2967\/jnumed.115.156505","article-title":"Dose-finding quantitative 18F-FDG PET imaging study with the oral pan-AKT inhibitor GSK2141795 in patients with gynecologic malignancies","volume":"56","author":"Gungor","year":"2015","journal-title":"J. Nuclear Med."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0135","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10637-017-0504-6","article-title":"Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations","volume":"35","author":"Hasegawa","year":"2017","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0140","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-16-2888","article-title":"A first-in-human, phase I, dose-escalation study of TAK-117, a selective PI3K\u03b1 isoform inhibitor, in patients with advanced solid malignancies","volume":"23","author":"Juric","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0145","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-kinase \u03b1-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study","volume":"36","author":"Juric","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0150","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0155","doi-asserted-by":"crossref","first-page":"100546","DOI":"10.1016\/j.gore.2020.100546","article-title":"Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)","author":"Lee","year":"2020","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0160","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.ejca.2012.06.027","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K\/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies","volume":"48","author":"Mahadevan","year":"2012","journal-title":"Eur. J. Cancer (Oxford, England\u202f: 1990)"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0165","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1158\/1078-0432.CCR-17-0725","article-title":"A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors","volume":"23","author":"Mateo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0170","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.18632\/oncotarget.27251","article-title":"Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study","volume":"10","author":"Piha-Paul","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0175","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00280-018-3610-z","article-title":"Phase 1\/1b dose escalation and expansion study of BEZ235, a dual PI3K\/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer","volume":"82","author":"Rodon","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0180","series-title":"First-in-human study of PF-05212384 (PKI-587), a Small-molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer","first-page":"1888","volume":"21","author":"Shapiro","year":"2015"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0185","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10147-010-0177-z","article-title":"Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases","volume":"16","author":"Takano","year":"2011","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0190","doi-asserted-by":"crossref","first-page":"v333","DOI":"10.1093\/annonc\/mdx372.006","article-title":"Actionable molecular alterations in advanced gynecologic malignancies: first results from the ProfiLER program (NCT01774409) in France","volume":"28","author":"Varnier","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0195","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/s41416-020-01041-x","article-title":"Phase 1 study of mTORC1\/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer","volume":"123","author":"Voss","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0200","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejca.2018.03.012","article-title":"First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1\/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67\/13)","volume":"96","author":"Wicki","year":"2018","journal-title":"Eur. J. Cancer (Oxford, England\u202f: 1990)"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0205","series-title":"Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers","first-page":"5672","volume":"20","author":"Yap","year":"2014"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0210","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s10637-018-0591-z","article-title":"A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors","volume":"36","author":"Aghajanian","year":"2018","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005747","article-title":"mTORC1 inhibition is required for sensitivity to PI3K p110\u03b1 inhibitors in PIK3CA-mutant breast cancer","volume":"5","author":"Elkabets","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0220","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0225","first-page":"1538","article-title":"Mechanisms of resistance to PI3K inhibitors in cancer","volume":"13","author":"Wright","year":"2021","journal-title":"Adapt. Resp. Drug Tolerance Cell. Plasticity"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0230","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/cancers12040802","article-title":"ER and PI3K pathway activity in primary ER positive breast cancer is associated with progression-free survival of metastatic patients under first-line tamoxifen","volume":"12","author":"Sieuwerts","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0235","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ygyno.2019.10.004","article-title":"Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility","volume":"155","author":"Fehniger","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2015.11.001","article-title":"Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer","volume":"53","author":"Lambrechts","year":"2016","journal-title":"Eur. J. Cancer (Oxford, England\u202f: 1990)"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0245","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/1535-7163.MCT-10-1089","article-title":"PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer","volume":"10","author":"Gonzalez-Angulo","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0250","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12032-019-1326-5","article-title":"Inhibition of PI3K\/AKT\/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors","volume":"37","author":"Perez-Juarez","year":"2019","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0255","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","article-title":"Olaparib and \u03b1-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial","volume":"20","author":"Konstantinopoulos","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0260","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1634\/theoncologist.2019-0297","article-title":"Phase Ib study of combination therapy with MEK inhibitor binimetinib and phosphatidylinositol 3-kinase inhibitor buparlisib in patients with advanced solid tumors with RAS\/RAF alterations","volume":"25","author":"Bardia","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2021.07.008_bb0265","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/annonc\/mdw672","article-title":"Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer","volume":"28","author":"Matulonis","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.008_bb0270","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821005382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821005382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:59:59Z","timestamp":1758772799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821005382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0090825821005382"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.07.008","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effectiveness of monotherapy with PI3K\/AKT\/mTOR pathway inhibitors in ovarian cancer: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}